BROIDRICK AMY S.

Président/Directeur Scientifique

OtherF

US·SEC (Form 4)

Qualigen Therapeutics, Inc.

0

Total declarations

0

Company

€17,815

▲ Purchases (1 ops.)

—

▼ Sales (0 ops.)

Discover the detailed record of transactions filed by BROIDRICK AMY S., Président/Directeur Scientifique. Director active across 1 companies, notably Qualigen Therapeutics, Inc.. Aggregated, 1 filings have been logged. Total volume traded: €18k. The latest transaction was disclosed on 14 June 2022 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.

Declarations1 total

Executives▲PurchaseQQualigen Therapeutics, Inc.35SEC

B

BROIDRICK AMY S.President/CSO

€17,81530,000 shares@ €0.5938100.0% of flow

Common Stock

SEC:0001493152-22-016857:0·14 Jun 2022

Ideal exit: 11 Mar 2023 (T+270)

SEC ↗

1 of 1 declaration

About BROIDRICK AMY S.

Amy S. Broidrick is the President and Chief Scientific Officer at Qualigen Therapeutics, Inc. She is responsible for the scientific and strategic leadership of the company, overseeing research and development initiatives. Her expertise in the pharmaceutical field is essential in guiding innovation and growth.